Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
KROS Stock Chart & Stats
$17.04
-$0.58(-3.66%)
At close: 4:00 PM EST
$17.04
-$0.58(-3.66%)
Day’s Range― - ―
52-Week Range$9.12 - $22.55
Previous CloseN/A
Volume109.28K
Average Volume (3M)308.90K
Market Cap
$519.14M
Enterprise Value-$2.70M
Total Cash (Recent Filing)$693.47M
Total Debt (Recent Filing)$17.43M
Price to Earnings (P/E)11.0
Beta0.75
Next Earnings
Mar 04, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding30,466,068
10 Day Avg. Volume262,348
30 Day Avg. Volume308,905
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)1.04
Price to Sales (P/S)166.94
P/FCF Ratio-3.64
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$21.50Price Target Upside26.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Corporate FocusRefocusing R&D exclusively on KER-065 and proposing a capital return concentrates corporate resources on the program with the greatest perceived value creation potential.
Clinical DataPhase I results for KER-065 demonstrated consistent improvements in lean mass, muscle volume, bone density, and related biomarkers, supporting the drug's potential to treat muscle and bone disorders.
Partnership And LicensingThe Takeda licensing agreement, including an upfront payment and milestone/royalty framework, validates the Activin platform and provides non-dilutive financial upside tied to KER-065's success.
Bears Say
Pipeline Concentration RiskDiscontinuation of cibotercept due to pericardial effusion adverse events and insufficient topline data reduces program diversification and increases dependence on KER-065 for future growth.
Regulatory UncertaintyUnclear outcomes from regulator discussions create ambiguity around the timing of a Phase II initiation, which could delay development milestones and reduce investor visibility.
Safety ProfileA dose-dependent increase in hemoglobin observed with KER-065 raises safety concerns that could necessitate additional monitoring, altered dosing, or further safety studies.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $9.12 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics’s market cap?
Keros Therapeutics’s market cap is $519.14M.
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Mar 04, 2026 which is in 18 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$1.135 by $0.955.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 30,466,068 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$1.135. Following the earnings report the stock price went up 3.323%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.50 (26.17% Upside)
$21.50 (26.17% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 655.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.2%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.41%
12-Months-Change
Fundamentals
Return on Equity
10.43%
Trailing 12-Months
Asset Growth
28.23%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$21.50
▲(26.17% Upside)
Technical Analysis
Gyre Therapeutics
―
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---